Flagship Pioneering
 | This article, Flagship Pioneering, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| Company type | Private |
|---|---|
| Founded | 1999 |
| Headquarters | , United States |
Key people |
|
| Website | www |
Flagship Pioneering is an American life sciences company based in Cambridge, Massachusetts[1][2][3] that founds biotechnology, life sciences, health and sustainability companies,[4] including the biotechnology company Moderna.[5] The firm is known for funding companies that it creates and incubates in-house.[6]
History
The company was founded in Cambridge in 1999 by Noubar Afeyan under the name NewcoGen (short for "new company generation"). A few years later, the name was changed to Flagship Ventures, and again in 2016 to Flagship Pioneering.[2]
In late 2010, Flagship formed Moderna, which focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA (mRNA).[5][7]
References
- ^ Fry, Erika (May 19, 2020). "How the biotech investor behind Moderna is using the 'immigrant mindset' to take on COVID-19". Fortune.
- ^ a b Stendahl, Max (December 15, 2016). "A new name and new fund will ensure Cambridge's Flagship 'feels like a startup'". Boston Business Journal.
- ^ Saltzman, Jonathan (April 2, 2020). "VC firm Flagship Pioneering raises $1.1b for biotech startups, despite reeling economy". Boston Globe.
- ^ National Research Council, Division on Earth and Life Studies, Board on Chemical Sciences and Technology, Committee on Challenges in Chemistry Graduate Education (2012). Challenges in Chemistry Graduate Education: A Workshop Summary. National Academies Press. p. 42. ISBN 978-0-309-25708-4.
{{cite book}}: CS1 maint: multiple names: authors list (link) - ^ a b Dunn, Andrew (May 23, 2020). "The untold story of Moderna as the biotech's coronavirus vaccine faces a test that could make it one of the most consequential startups of all time". Business Insider.
- ^ DeAngelis, Allison (April 2, 2020). "With $1.1B in hand, life sciences investor Flagship rewrites its rulebook". Boston Business Journal.
- ^ Garde, Damian (November 10, 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat.